---
figid: PMC9627904__gr6
figtitle: 2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for
  Type 2 Diabetes
organisms:
- Rattus norvegicus
- Cavia porcellus
- Malus domestica
- Zootoca vivipara
- Heloderma suspectum
- Homo sapiens
- Canis lupus familiaris
organisms_ner:
- Drosophila melanogaster
pmcid: PMC9627904
filename: gr6.jpg
figlink: /pmc/articles/PMC9627904/figure/undfig2/
number: F6
caption: Consensus Pathway on Novel Therapy for Type 2 DiabetesSGLT2 inhibitors include
  those with proven efficacy, including empagliflozin, canagliflozin, and dapagliflozin.
  GLP-1RAs include those with proven efficacy, including liraglutide, semaglutide,
  and dulaglutide. ASCVD = atherosclerotic cardiovascular disease; eGFR = estimated
  glomerular filtration rate (mL/min/1.73 m2); GLP-1 RA = glucagon-like peptide 1
  receptor agonist; HF = heart failure; LVEF = left ventricular ejection fraction;
  PCE = Pooled Cohort Equation; RF = risk factor; SGLT2 i = sodium-glucose cotransporter
  2 inhibitor.
papertitle: 2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for
  Type 2 Diabetes.
reftext: Chern-En Chiang, et al. JACC Asia. 2021 Sep;1(2):129-146.
year: '2021'
doi: 10.1016/j.jacasi.2021.08.003
journal_title: JACC Asia
journal_nlm_ta: JACC Asia
publisher_name: Elsevier
keywords: antidiabetic agents | chronic kidney disease | heart failure | Taiwan Society
  of Cardiology | type 2 diabetes | ASCVD, atherosclerotic cardiovascular disease
  | CKD, chronic kidney disease | CV, cardiovascular | eGFR, estimated glomerular
  filtration rate | HF, heart failure | GLP-1RA, glucagon-like peptide 1 receptor
  agonist | MACE, major adverse cardiovascular events | SGLT2, sodium-glucose cotransporter
  2
automl_pathway: 0.9272963
figid_alias: PMC9627904__F6
figtype: Figure
redirect_from: /figures/PMC9627904__F6
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9627904__gr6.html
  '@type': Dataset
  description: Consensus Pathway on Novel Therapy for Type 2 DiabetesSGLT2 inhibitors
    include those with proven efficacy, including empagliflozin, canagliflozin, and
    dapagliflozin. GLP-1RAs include those with proven efficacy, including liraglutide,
    semaglutide, and dulaglutide. ASCVD = atherosclerotic cardiovascular disease;
    eGFR = estimated glomerular filtration rate (mL/min/1.73 m2); GLP-1 RA = glucagon-like
    peptide 1 receptor agonist; HF = heart failure; LVEF = left ventricular ejection
    fraction; PCE = Pooled Cohort Equation; RF = risk factor; SGLT2 i = sodium-glucose
    cotransporter 2 inhibitor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CG1136
  - 'On'
  - rf
  - Egfr
  - Hf
  - et
  - Empagliflozin
  - Canagliflozin
  - Dapagliflozin
  - Type 2 Diabetes
  - cardiovascular
  - renal diseases
  - Stroke
---
